Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Anti-myocardial ischemia effect of Syringa pinnatifolia Hemsl. by inhibiting expression of cyclooxygenase-1 and -2 in myocardial tissues of mice
Yuan Cao,Jing Wang,Guozhu Su,Yan Wu,Ruifeng Bai,Qian Zhang,Xiao-Li Gao,Chun Li,Suyile Chen,Pengfei Tu,Xingyun Chai +10 more
TL;DR: Intragastric pretreatment with SP produced a dose-dependent increase in cardiac function and substantial evidence to support the clinical application of SP is shown and indicates that such medicine has great potential for treating ischemia-induced heart disease.
Journal ArticleDOI
Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk.
Peter Creighton Elwood,Gareth Morgan,Julieta Galante,Julieta Galante,John Whay Kuang Chia,Sunil Dolwani,J. Michael Graziano,Mark Kelson,Angel Lanas,Marcus Longley,Ceri Phillips,Janet Elizabeth Pickering,Stephen E. Roberts,Swee Sung Soon,William P. Steward,Delyth Morris,Alison Lesley Weightman +16 more
TL;DR: The majority of the adverse events caused by aspirin are GI bleeds, and there appears to be no valid evidence that the overall frequency of fatalGI bleeds is increased by aspirin.
Journal ArticleDOI
Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1
TL;DR: A common genetic variant in PEAR1 (rs12041331) reproducibly influenced platelet aggregation in aspirin-treated patients with coronary artery disease, and the effect of this polymorphism may be related to changes in platelet activation.
Journal ArticleDOI
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
Jeremiah Fairbanks,Audrey Umbreit,Bhanu Prakash Kolla,Victor M. Karpyak,Terry D. Schneekloth,Larissa L. Loukianova,Shirshendu Sinha +6 more
TL;DR: This review focuses on the use of Baclofen, a γ-aminobutyric acid B receptor agonist used for spasticity and pain, which received temporary approval for alcohol use disorder in France.
Journal ArticleDOI
Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.
Sanne Bøjet Larsen,Erik Lerkevang Grove,Søs Neergaard-Petersen,Morten Würtz,Anne-Mette Hvas,Steen Dalby Kristensen +5 more
TL;DR: In this paper, the antiplatelet effect of aspirin was assessed by measurement of platelet aggregation employing multiple electrode aggregometry (MEA, Multiplate Analyzer) in whole blood anticoagulated with citrate or hirudin using arachidonic acid (AA) or collagen as agonists, and VerifyNow Aspirin Assay.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.